Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the main issues concerning the use of CSF and carried out a consensus process about the use of CSF in cancer patients, held in Madrid on 26 May 2006. The group concluded the following recommendations: prophylactic use of CSF is recommended when a rate of febrile neutropenia (FN) higher than 20% is expected without the use of CSF or when additional risk factors for neutropenia exist; therapeutic use of CSF is recommended in order to treat FN episodes but not to treat afebrile neutropenic episodes. In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens.
Carrato
Alfredo
A
Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain. acarrato@telefonica.net
Paz-Ares Rodríguez
Luis
L
Rodríguez Lescure
Alvaro
A
Casas Fernández de Tejerina
Ana M
AM
Díaz Rubio García
Eduardo
E
Pérez Segura
Pedro
P
Constenla Figueiras
Manuel
M
García Carbonero
Rocío
R
Gómez Codina
José
J
Lluch Hernández
Ana
A
Maroto Rey
José Pablo
JP
Martín Jiménez
Miguel
M
Mayordomo Cámara
José Ignacio
JI
Moreno Nogueira
José Andrés
JA
Rueda Domínguez
Antonio
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control* / Q000652:urine; D013030:Spain
D003115:Colony-Stimulating Factors